Full-service biopharmaceutical contract manufacturing organisation (CMO), is starting to expand its facilities, buildings and laboratory units at the company's site in Laupheim, Germany
This will increase production capacities for antibodies and mammalian cell culture-derived proteins.
"By expanding our production capacity we will establish Rentschler Biotechnologie as a market supplier of antibodies," explains Nikolaus Rentschler, CEO at Rentschler Biotechnologie.
The Rentschler group of companies, which recently sold its OTC business, will invest 50 million euros in its biotechnology segment to build two fermentation suites with a total volume of 5000 litres for market production and several smaller suites ranging from 250 to 500 litres for clinical supplies.
These will create more than 100 jobs for highly skilled specialists.
The expansion is progressing gradually and the first new production line is planned to go into operation early in 2008.
In the future, ten independent GMP facilities will be available for the production of biopharmaceuticals.
At its 3500m2 state-of-the-art facilities in Laupheim, Rentschler Biotechnologie presently possesses the capacity for manufacturing clinical supplies as well as market supply of low-dosed drugs such as cytokines.
By setting up additional fermenter suites, the Rentschler group will strengthen its biotechnology business of custom manufacturing services from cell line development to large-scale cGMP production, registration of drugs and fill and finish.
Based in Laupheim, Germany, Rentschler Biotechnologie is part of the privately held Rentschler group of pharmaceutical companies.
As a full-service contract manufacturer with a highly skilled staff of 250, Rentschler Biotechnologie has 30 years of experience in drug development, production and approval of biopharmaceuticals compliant with international GxP standards.
The company's area of expertise also includes regulatory affairs and fill and finish.
Among the pioneers in the development and production of biotech drugs, Rentschler was the first company to gain market authorization for an interferon-containing drug.
